Introduction

Joint wear can affect mobility and everyday life, causing pain and restricting movement. When non-surgical management alone has not provided sufficient relief, patients and clinicians may consider whether a biologically active intervention — short of surgery — could help preserve the joint. This article focuses on the ChondroFiller injection, a non-surgical, minimally invasive option, with realistic expectations throughout.

What Does the ChondroFiller Injection Involve?

ChondroFiller is an ultrasound-guided injection. The device itself is a Class III CE-marked acellular type I collagen hydrogel scaffold (manufactured by Meidrix Biomedicals, Germany). When the two-component system is injected, the liquid collagen solution gels within approximately three to five minutes, filling the contours of the cartilage defect and forming a self-adherent scaffold. There is no incision, no theatre, and no general anaesthetic.

The scaffold is cell-free by design. It works by providing a chemotactic matrix that attracts the patient's own progenitor cells from the surrounding synovium and subchondral bone marrow. Over time these cells may differentiate and deposit new cartilage-like tissue, gradually replacing the scaffold as it resorbs. Evidence suggests this process unfolds over twelve months and beyond, with imaging and patient-reported outcomes continuing to improve over twelve to thirty-six months.

Is It a Complicated Procedure?

The ChondroFiller injection is straightforward in terms of patient experience. Ultrasound guidance allows precise placement through a fine needle rather than an incision, with minimal disruption to surrounding tissue. The procedure is performed in an outpatient setting; no hospital admission is required. Because no tissue is removed and no operation is performed, the risks associated with surgery — such as infection at a surgical site, anaesthetic complications, and extended recovery — do not apply.

Who May Be Suitable?

ChondroFiller is not appropriate for every joint problem, and suitability requires individual clinical assessment. It has CE marking for ICRS Grade I–IV cartilage defects up to 6 cm² across a range of joints, including the knee, hip, ankle, and smaller joints such as the trapeziometacarpal joint of the thumb. In published clinical series, it has been used for localised osteoarthritis and focal cartilage wear rather than advanced, end-stage joint disease.

It may be a reasonable option for patients who want to avoid or delay surgery, provided the defect is accessible by injection and the degree of wear is within the device's indicated range. It is not a treatment for widespread, severe arthritis, and benefits cannot be guaranteed.

What Does 'Minimally Invasive' Mean Here?

In the context of the ChondroFiller injection, 'minimally invasive' refers specifically to the non-surgical delivery route: an ultrasound-guided needle placement, no incision, and no surgical recovery period. This is distinct from minimally invasive surgery, which still involves an operation under anaesthetic — for example, the keyhole (arthroscopic) techniques used in surgical cartilage procedures. The ChondroFiller injection is non-surgical in the full sense.

It is best understood as a regenerative, joint-preserving injection rather than a cure or a reversal of arthritis. Clinical experience indicates it may reduce pain and support function for some patients, but individual responses vary and the underlying joint disease is not eliminated.

What Does the Evidence Show?

Published data supporting ChondroFiller as a device — collected from CE-marking clinical evaluations and independent investigations — show clinically meaningful improvements in patient-reported outcomes. In knee studies, International Knee Documentation Committee (IKDC) scores have improved by approximately thirty points over twelve to thirty-six months. In hip studies, modified Harris Hip Score (mHHS) improvements of more than thirty points have been reported. MRI assessment of repair tissue quality (MOCART scoring) has reached around eighty and above in knee and hip cohorts, indicating good defect fill and integration.

An independent study by Corain et al. (2023) in Cartilage reported significant pain reduction and functional improvement following ChondroFiller injection into the trapeziometacarpal joint in thumb osteoarthritis, extending the evidence beyond the knee.

The safety profile across more than 19,000 units sold since 2013 is notable: no serious incidents have been reported, and the overall complaint rate is very low. The most common device-related issue — failure to gel — occurs at a very low frequency and is usually attributable to handling rather than a device defect.

Patient Experience and Recovery

Because the ChondroFiller injection is non-surgical, recovery is straightforward for most patients. There is no surgical incision to heal and no requirement for the structured rehabilitation that follows arthroscopic or open surgery. Mild discomfort at the injection site typically settles within a few days. Patients are usually able to return to normal daily activities promptly, with sensible load management and, where clinically indicated, physiotherapy support in the weeks following the injection.

The regenerative process is gradual. Patients should not expect immediate pain relief equivalent to a corticosteroid injection; the biological activity of the scaffold unfolds over months, and clinical benefit tends to become clearer at the three-to-six-month mark and beyond.

How Does the ChondroFiller Injection Relate to Liquid Cartilage?

It is worth clarifying the terminology, as patients sometimes encounter both names. ChondroFiller is the device — the collagen scaffold. It can be delivered either by injection (non-surgical, ultrasound-guided, as described throughout this article) or arthroscopically as part of a surgical procedure.

Liquid Cartilage is a different and separate concept: it is the Lee Liquid Cartilage Protocol, a keyhole (arthroscopic) surgical technique developed by Professor Paul Y. F. Lee at the London Cartilage Clinic. It involves placing the ChondroFiller scaffold surgically, combined with biological adjuncts such as platelet-rich fibrin or plasma, and where indicated the patient's own mesenchymal stem cells (from bone-marrow concentrate or micro-fragmented fat). Liquid Cartilage is genuine surgery — it requires theatre, anaesthetic, and a structured recovery programme. It is used for larger or load-bearing cartilage defects, typically in the knee, hip, shoulder, or ankle.

The two pathways share the same scaffold material but are clinically distinct. The ChondroFiller injection suits accessible lesions and patients who want a non-surgical route; the Liquid Cartilage surgical protocol suits more complex defects where the additional biological and surgical environment is warranted.

Conclusion

The ChondroFiller injection offers a non-surgical, ultrasound-guided option for patients with localised cartilage wear or osteoarthritis who wish to explore a biologically active approach before considering surgery. The CE-marked collagen scaffold recruits the body's own cells to support cartilage repair, with published evidence of clinically meaningful improvements in pain and function across knee, hip, and other joints. Benefits vary, and results depend on individual clinical factors.

For patients with more extensive defects or those requiring a surgical approach, the Liquid Cartilage keyhole procedure offers a distinct, more intensive pathway. A specialist assessment is essential to determine which option, if either, is appropriate. The London Cartilage Clinic offers expert evaluation of cartilage and joint-preservation options, including assessment for both the ChondroFiller injection and the Liquid Cartilage surgical protocol.

References

Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller® Liquid for trapeziometacarpal osteoarthritis. Cartilage.